5-氨基-2,6-二甲基-4-嘧啶醇 | 93933-83-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 5-氨基-2,6-二甲基-4-嘧啶醇
• 英文名称: 5-amino-2,6-dimethyl-3H-pyrimidin-4-one
• 英文别名: 5-Amino-2,6-dimethyl-3H-pyrimidin-4-on；5-Amino-2,6-dimethylpyrimidin-4-ol；5-amino-2,4-dimethyl-1H-pyrimidin-6-one
• CAS: 93933-83-6
• 化学式: C₆H₉N₃O
• mdl: MFCD00806966
• 分子量: 139.157
• InChiKey: LKKSPQLDRZTINU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  67.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-氨基-2,6-二甲基-4-嘧啶醇 在 三氯氧磷 作用下， 生成 N-(4-chloro-2,6-dimethyl-pyrimidin-5-yl)-formamide
  参考文献：
  名称：

  Hull et al., Journal of the Chemical Society, 1947, p. 41,45

  摘要：

  DOI：
• 作为产物：
  描述：

  2-甲基-4,6-二氯-5-硝基嘧啶 在 盐酸 、 甲醇 、 palladium on activated charcoal 作用下， 生成 5-氨基-2,6-二甲基-4-嘧啶醇
  参考文献：
  名称：

  来自5-氨基嘧啶的1：2：4：6-四氮杂茚满和1：4：6-三氮杂丹-2-酮

  摘要：

  DOI：

  10.1039/jr9540004116

文献信息

• Synthèse d'amino-5-pyrimidines et des sulfanilamids correspondants
  作者：R. Urban、O. Schnider

  DOI：10.1002/hlca.19580410635

  日期：——

  Durch Alkyl- und Alkoxy-Gruppen substituierte 5-Amino-pyrimidine wurden nach verschiedenen Methoden synthetisiert. Einige der daraus hergestellten Sulfanilamide zeichnen sich durch intensive und langdauernde chemotherapeutische Wirkung aus.

  通过各种方法合成被烷基和烷氧基取代的5-氨基嘧啶。由它们制得的一些磺酰苯胺具有强烈而持久的化学治疗作用。
• Reaction of 2,6-dimethyl-4-hydroxy-5-aminopyrimidine with the vilsmeier reagent
  作者：O. S. Sizova、R. G. Glushkov

  DOI：10.1007/bf00776799

  日期：1984.6

  convenient is a method based on the cyclization of substituted 4-methyl-5-aminopyrimidines with the Vilsmeier reagent (VR), which proceeds with the formation of 7-(N,N-dimethylammoniamethylidene)pyrrolo[3,2-c]pyrimidine chloride derivatives [i]. In connection with the fact that the scheme of this reaction has not yet been elucidated, we made attempts to study the possible pathways of the formation of

  在描述的 [3] 制备吡咯并嘧啶的方法中，最方便的方法之一是基于取代的 4-甲基-5-氨基嘧啶与 Vilsmeier 试剂 (VR) 的环化，该方法继续形成 7- (N,N-二甲基氨亚甲基)吡咯并[3,2-c]嘧啶氯化物衍生物[i]。结合该反应的路线尚未阐明的事实，我们试图研究在2,6-二甲基丙烯酰环化情况下该双环体系吡咯片段形成的可能途径。 -4-羟基-5-氨基嘧啶(I)在th-VR的帮助下转化为2-甲基-4-羟基-7-(N,N-二甲基氨亚甲基)吡咯并[3,2,2d]嘧啶氯化物(II)。应该指出的是，之前已经尝试研究类似的过程，并在 VR 的帮助下分离 2-氨基-3-甲基吡嗪环化中的中间体，VR 继续形成 7-(N, N-二甲基氨亚甲基)吡咯并[2,3-b]吡嗪化合物[4]。然而，这些尝试并没有给出积极的结果。
• YIGSR peptidomimetics and methods for using the same
  申请人：——

  公开号：US20030199531A1

  公开（公告）日：2003-10-23

  YIGSR peptidomimetics and methods for making and using the same are provided. The subject YIGSR peptidomimetics are non-peptidic, biodegradation-resistant molecules that mimic the pentapeptide tyrosine-isoleucine-glycine-serine-arginine (YIGSR) binding site for the 67 kiloDalton (kDa) laminin binding protein (LBP). The subject peptidomimetics include a rigid or substantially rigid non-peptidic scaffold that effectively presents or positions a tyrosine or tyrosine-like group, an isoleucine or isoleucine-like group, a serine or serine-like group, and an arginine or arginine-like group in substantially the same manner as occurs in the YIGSR peptide itself. The subject peptidomimetics find use in a variety of different applications, including diagnostic and therapeutic applications.

  提供了 YIGSR 拟肽物及其制造和使用方法。所述 YIGSR 拟肽物是非肽、抗生物降解分子，可模拟 67 千道尔顿（kDa）层粘连蛋白（LBP）的五肽酪氨酸-异亮氨酸-甘氨酸-丝氨酸-精氨酸（YIGSR）结合位点。这种多肽模拟物包括一个刚性或基本刚性的非肽支架，它以与 YIGSR 肽本身基本相同的方式有效地呈现或定位酪氨酸或酪氨酸样基团、异亮氨酸或异亮氨酸样基团、丝氨酸或丝氨酸样基团以及精氨酸或精氨酸样基团。这种多肽模拟物可用于各种不同的应用，包括诊断和治疗应用。
• Andersag; Westphal, Chemische Berichte, 1937, vol. 70, p. 2035,2044
  作者：Andersag、Westphal

  DOI：——

  日期：——
• Effects of Transdermal Testosterone on Cognitive Function and Health Perception in Older Men With Low Bioavailable Testosterone Levels
  作者：A. M. Kenny、S. Bellantonio、C. A. Gruman、R. D. Acosta、K. M. Prestwood

  DOI：10.1093/gerona/57.5.m321

  日期：2002.5.1

  Background. Many men older than 50 years have bioavailable testosterone levels below the reference range for young adult men. The impact of the decreased androgen levels oil cognition and health perception has received little attention.Methods. Sixty-seven men (mean age 76 +/- 4 years, range 65-87) with bioavailable testosterone levels below 128 ng/dl (lower limit for adult normal range) were randomized to receive transdermal testosterone (2-2.5 mg patches/d) or placebo patches for I year. All men received 500 mg Supplemental calcium and 400 IU vitamin D. Outcome measures included sex hormones [testosterone, bioavailable testosterone, sex hormone binding globulin (SHBG), estradiol, and estrone], cognitive tests, (Digit Symbol, Digit Span, Trailmaking A and B), health perception (Medical Outcome Survey Short-form 36 or SF-36), lower extremity muscle strength and power. and calcium intake.Results. Twenty-three men (34%) withdrew from the Study; 44 men completed the trial. Bioavailable testosterone levels increased from 93 +/- 34 (SD) to 162 +/- 100 ng/dl (p < .002) at 12 months in the testosterone group (n = 24) while no change occurred in the control group (n 20). While there was no change in estradiol levels in either group, estrone levels increased in the testosterone group (28 +/- 7 to 32 +/- 9 pg/dl, p = .017). Scores oil the Digit Symbol test improved in both the testosterone and placebo groups. Scores on Trailmaking B improved in men treated with testosterone (p < .005), although the changes were not statistically different from the changes seen in the placebo group. Twelve-month scores on Trailmaking B for the entire group were correlated with 12-month testosterone levels (p = .016). Scores for health perception measured by SF-36 did not change significantly, though scores of mental and general health declined in both groups during the 12-month intervention. Twelve-month bioavailable testosterone scores were directly correlated with scores for physical role (p = .022), vitality (p = .036), and the physical composite score (p = .010).Conclusions. Transdermal testosterone treatment in men with low bioavailable testosterone levels does not impair and may improve cognitive function. Treatment did not improve health perception but this may have been due to the side effects of skin irritation suggested by similar reactions in both the testosterone and placebo groups.